What Researchers Did
This review examined the current understanding of oxidative and endoplasmic reticulum stress in multiple sclerosis and evaluated the effects of hyperoxia treatments on neural cells.
What They Found
While multiple sclerosis patients have reported symptom improvement, particularly in bladder control, since 1970 through self-management with hyperbaric oxygen, the majority of clinical trial evidence does not support these patient observations. The review highlighted a discrepancy between anecdotal patient reports and the lack of robust clinical trial data.
What This Means for Canadian Patients
Canadian patients with multiple sclerosis considering hyperbaric oxygen therapy should be aware that while some patients report benefits, current clinical trial evidence largely does not support its effectiveness. It is crucial to discuss all treatment options with a healthcare provider to make informed decisions based on established medical evidence.
Canadian Relevance
This review article has no direct Canadian connection.
Study Limitations
A key limitation is the ongoing discrepancy between patient-reported benefits of hyperbaric oxygen therapy for multiple sclerosis and the lack of supporting evidence from clinical trials.